This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Ankylosing Spondylitis, Thoracic Region강직척추염, 흉추부

ICD-10M45.4
Synonyms / related termsAnkylosing spondylitis with thoracic involvement, chest wall fixation AS, thoracic AS, costovertebral arthritis
Special Copayment ReductionV140 — Severe intractable disease (copayment 10%, 5 years)
Main age of onsetOnset at ages 15-35; thoracic involvement progresses after sacroiliac joint-lumbar involvement

Contents

s1History
s2Causes
s3Genetics
s4General epidemiology
s5Pathophysiology
s6Symptoms
s7Signs
s8Screening
s9Diagnosis
s10Treatment
s11Prognosis
s12Prevention
s13References

1. History

Thoracic spine (T1-T12) involvement in ankylosing spondylitis (AS) includes the costovertebral joints (CVJ) and costotransverse joints, and unlike AS of other spinal regions, it causes a unique complication, restrictive lung disease due to reduced chest wall expansion. Historical descriptions of thoracic involvement progressed along with the history of AS in general, but the effect of chest wall rigidity on respiratory function has been systematically studied since the 1950s. Radiographically, increased thoracic kyphosis (thoracic hyperkyphosis), thoracic syndesmophytes, and CVJ ankylosis are characteristic of thoracic involvement in AS. In MRI studies in the 2000s, active thoracic bone marrow edema was identified at an early stage, making early diagnosis of non-radiographic thoracic involvement possible. When surgical correction (pedicle subtraction osteotomy) of exaggerated thoracic kyphosis (kyphotic deformity) is needed, a highly demanding technique is required.

2. Causes

The main causal risk factors of thoracic AS are the same as for systemic AS (HLA-B27, long disease duration, smoking, male sex), and the mechanical environment particular to the thoracic spine contributes to lesion progression. The thoracic spine is fixed by the ribs and is less mobile than the lumbar spine, but micromovements occur repeatedly during the respiratory cycle, placing repetitive load on the entheses of the CVJ and CTJ (costotransverse joint). Chronic enthesis inflammation at this site causes ankylosis of the CVJ and CTJ and sequentially reduces chest wall expansion. Smoking is the most important modifiable risk factor for progression of thoracic AS, and thoracic syndesmophyte formation is faster in smokers. Inadequate NSAID or biologic treatment also accelerates thoracic radiographic progression.

3. Genetics

The genetic basis of thoracic AS shares the genetic risk factors of systemic AS, such as HLA-B27, ERAP1, and IL23R. In addition, polymorphisms of TNFRSF11B (osteoprotegerin gene) affect the balance between osteoporosis risk and bone formation in AS and may contribute to the pattern of thoracic bone formation. The ANKH gene regulates inorganic pyrophosphate transport and affects the tendency toward ossification. Polymorphisms of the SMAD3 and BMP-4 genes may affect the extent and rate of thoracic ligament ossification and bony fusion. The severity of chest wall restrictive respiratory impairment differs according to the extent of thoracic involvement and the individual patient's bone-forming capacity (genetically determined).

4. General epidemiology

As for the epidemiology of thoracic involvement in AS, based on thoracic syndesmophyte formation, it occurs in about 50-70% of AS patients in the long term. Reduced chest wall expansion (chest expansion < 2.5 cm) is one of the AS diagnostic criteria, with a prevalence of about 30-50% of AS patients. Restrictive lung disease is identified by decreased FVC or TLC in about 10-30% of AS patients, and significant respiratory impairment occurs in about 5%. Thoracic fractures account for about 10-15% of all fractures in AS. Chest pain due to CVJ ankylosis is commonly reported in AS patients and must be differentiated from cardiac causes. Male sex, smoking, older age, and a high BASDAI score are risk factors for progression of thoracic involvement.

5. Pathophysiology

The pathology of thoracic AS begins with TNF-α/IL-17A inflammation of the entheses of the CVJ, CTJ, and thoracic disc-vertebral junctions. Because the CVJ and CTJ are true synovial joints, synovial proliferation, pannus formation, and reactive bone formation progress and cause joint ankylosis. Activation of BMP/Wnt signaling promotes thoracic syndesmophytes and ligament ossification. Exaggerated thoracic kyphosis arises from the combined contribution of bony fusion of the anterior wedge-shaped structure of the spine and shortening of the posterior ligaments. When expansion of the thoracic cage on inspiration becomes impossible because of CVJ/CTJ ankylosis, breathing shifts to diaphragm-dependent respiration, and diaphragmatic function is also affected in the long term. Osteoporosis in AS increases the risk of thoracic compression fracture, and compression fractures further worsen kyphotic deformity.

6. Symptoms

The main symptoms of thoracic AS are thoracic back pain (worse at rest, relieved by exercise), chest wall pain (worse on deep breathing or coughing), and morning thoracic stiffness. Chest pain due to CVJ/CTJ inflammation resembles costochondritis, pericarditis, and ischemic heart disease and requires differentiation. Dyspnea on exertion due to reduced chest wall expansion progresses gradually, and a restrictive pattern appears on pulmonary function tests. With moderate or greater exaggeration of thoracic kyphosis, forward shift of the center of gravity causes marked fatigue when standing or walking. A thoracic fracture presents with sudden worsening of thoracic back pain, and if nerve root or spinal cord compression is present, intercostal neuralgia, lower limb numbness, and gait disturbance occur.

7. Signs

A key clinical sign of thoracic involvement is chest expansion measurement (at the level of the 4th intercostal space, normal ≥ 2.5 cm), which is included in the modified New York diagnostic criteria for AS. Local thoracic tenderness (spinous processes and costovertebral junctions) and CVJ and CTJ tenderness are identified. The thoracic kyphosis angle is measured as the Cobb angle (normal 20-40°; > 50° in AS is severe deformity) and quantified with lateral radiographs. On lung auscultation, decreased breath sounds in the lower lung fields on inspiration and atelectatic sounds suggesting basal atelectasis may be heard. In a thoracic compression fracture, tenderness of the affected segment, shortening, and radiographic findings (vertebral wedge deformity) are observed.

8. Screening

For screening of thoracic AS, anteroposterior and lateral thoracic radiographs are performed to assess syndesmophytes, CVJ ankylosis, vertebral compression fractures, and the thoracic kyphosis Cobb angle. Pulmonary function tests (FVC, FEV1, TLC, DLCO) are essential for evaluating chest wall restrictive respiratory impairment, and regular follow-up testing is recommended. Chest HRCT excludes underlying lung lesions (AS-related apical pulmonary fibrosis, bronchiectasis) and evaluates structural causes of chest wall fixation. Thoracic MRI (T2/STIR) evaluates active CVJ/CTJ inflammation and active thoracic bone marrow edema. The 6-minute walk test and oxygen saturation measurement evaluate the functional impact of reduced pulmonary function. Electrocardiography and echocardiography exclude cardiac complications (AS-related aortic regurgitation, conduction disturbance).

9. Diagnosis

A diagnosis of thoracic AS is made when, in a patient meeting AS criteria, characteristic findings of thoracic AS (CVJ/CTJ ankylosis, thoracic syndesmophytes, active thoracic bone marrow edema) are identified on thoracic radiographs or MRI. Reduced chest wall expansion is included in the AS diagnostic criteria (clinical criterion 3). For differentiation from DISH (diffuse idiopathic skeletal hyperostosis), radiographic morphology is important (DISH: flowing ossification, mainly on the right, preserved disc height vs. AS: syndesmophytes, discitis, sacroiliac joint involvement). After excluding cardiac causes of chest pain, a CVJ/CTJ origin is confirmed. The Spondyloarthritis Research Consortium of Canada (SPARCC) score on thoracic MRI is used to quantify active thoracic inflammation.

10. Treatment

Drug treatment of thoracic AS applies the standard systemic AS treatment (NSAIDs first line, TNF inhibitors/IL-17A inhibitors second line). Respiratory rehabilitation (breathing exercises, chest expansion exercises, diaphragmatic breathing training) is essential for maintaining chest wall expansion and preserving pulmonary function. Swimming is recommended as an exercise especially effective for chest wall expansion. Surgical correction of thoracic kyphotic deformity (cervicothoracic or lumbar osteotomy, PSO) is considered when the deformity is severe, with loss of horizontal gaze, dysphagia, and severely reduced respiratory function. Vertebroplasty for thoracic compression fractures is applied selectively to osteoporotic fractures. Osteoporosis treatment (bisphosphonates, anti-RANKL) is essential for preventing thoracic fractures.

11. Prognosis

The prognosis of AS with thoracic involvement is determined by the degree of progression of chest wall restrictive respiratory impairment and the severity of thoracic kyphotic deformity. Mild to moderate chest wall restriction can have its functional impact minimized by active respiratory rehabilitation. Severe thoracic kyphosis (Cobb angle > 70°) markedly reduces quality of life and cardiopulmonary function. Neurological complications after a thoracic fracture cause paraplegia, and recovery is often incomplete. Evidence is accumulating that TNF/IL-17 inhibitor administration reduces the rate of thoracic syndesmophyte progression, but complete suppression is difficult. Coexisting AS-related cardiovascular complications (aortic regurgitation) are a factor worsening the prognosis.

12. Prevention

Prevention of thoracic AS consists of early diagnosis, vigorous anti-inflammatory treatment, smoking cessation, and thoracic exercise rehabilitation. Thoracic extension exercises (swimming, back extension exercises), deep breathing exercises, and exercises to maintain CVJ mobility are performed routinely. Smoking cessation is the most effective intervention for simultaneously suppressing the rate of thoracic radiographic progression and decline in pulmonary function. Regular pulmonary function tests allow early detection of chest wall restrictive respiratory impairment and initiation of respiratory rehabilitation. Osteoporosis management (vitamin D/calcium, anti-osteoporosis treatment) reduces the risk of thoracic compression fracture. Environmental modification to reduce the risk of falls that could cause thoracic compression fractures is also important.

13. References

1. van der Linden S, et al. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum. 1984;27(4):361-8.

2. Sieper J, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8-18.

3. Braun J, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.

4. Poddubnyy D, et al. Rates and predictors of radiographic spinal progression in AS. Ann Rheum Dis. 2011;70(8):1369-74.

5. Baraliakos X, et al. MRI in AS: patterns of spinal changes. Rheumatology. 2017;56(3):421-32.

6. Reveille JD. Genetics of spondyloarthritis — beyond the MHC. Nat Rev Rheumatol. 2012;8(5):296-304.

7. Klingberg E, et al. Osteoporosis in ankylosing spondylitis — prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.

8. Ramiro S, et al. ASAS-EULAR recommendations for AS management: 2022 update. Ann Rheum Dis. 2023;82(1):19-34.

9. Kim TH, et al. Spondyloarthropathies in Korea: prevalence and clinical characteristics. J Korean Med Sci. 2021;36(12):e96.

10. Wanders AJ, et al. NSAIDs inhibit radiographic progression in AS. Arthritis Rheum. 2005;52(6):1756-65.